Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing

Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…

AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.

Quorum Health strikes deal to become nonprofit

Kelly Gooch / beckershospitalreview - Quorum Health, a for-profit system headquartered in Brentwood, Tenn., has signed a definitive agreement with nonprofit health system Healthside Partners to transition Quorum into a nonprofit organization spanning 11 hospitals across nine states. With the …

AI Summary: Quorum Health agreed to become a nonprofit through a transaction with Healthside Partners to avert insolvency, rescue struggling hospitals, and stabilize finances. Executives frame the conversion as a survival strategy to maintain care access, restructure operations, and shift priorities from profitability to community health amid mounting fiscal pressure.

GHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investor

Reynald Castaneda / endpoints - European healthcare investor GHO Capital and asset management firm CBC Group are set to join forces, with the new entity to manage over $21 billion. In a Wednesday release, they said ...

AI Summary: GHO Capital and CBC Group have agreed to combine their healthcare investment platforms to create roughly a $21 billion specialist investor focused on health assets. The tie-up consolidates capital and deal teams to chase larger transactions across care delivery, pharma and tech—because apparently healthcare needed a bigger private-equity behemoth.

UCB bets $2 billion on Candid's T cell engager ambitions

Kyle LaHucik / endpoints - Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is paying $2 ...

AI Summary: UCB has struck a roughly $2 billion deal to acquire Candid, betting heavily on Candid’s T‑cell engager platform to reset immune‑based oncology programs. The acquisition boosts UCB’s immuno‑oncology pipeline and signals intensified competition in T‑cell engager development, with investors and researchers watching closely to see how science translates into clinical wins.

Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M

fiercehealthcare - The deal, expected to close later this year, is another attempt from the major rural nonprofit system to enter the Minneapolis market. To do so, it plans a $600 million investment into two-hospital North Memorial Health that will help stabilize one financ…

AI Summary: Sanford Health announced a plan to integrate Minnesota-area North Memorial Health with a $600 million investment, creating a combined system aimed at expanding services, streamlining care and gaining scale. The transaction is part of a broader wave of regional healthcare consolidation as systems chase efficiency and market presence.

Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M

fiercehealthcare - The deal would bring the 40-year-old, publicly traded company under a growth-oriented investment firm with a prior background in healthcare staffing.

AI Summary: Staffing firm Cross Country Healthcare agreed to be taken private in a $437 million deal by private equity buyer Knox Lane, ending its public-company chapter. The acquisition positions the firm for strategic repositioning and could reverberate across hospital staffing markets as investors consolidate workforce services.

WakeMed Health's plans to join Atrium Health face swift pushback from NC officials

fiercehealthcare - A combination unveiled May 1 would bring WakeMed Health $2 billion in promised investment from the major nonprofit system. State officials voiced concerns about the impact of such consolidation and the value of those commitments, delaying a planned go-ahe…

AI Summary: Atrium Health’s plan to fold WakeMed into its system — backed by a roughly $2 billion investment plan — is running into immediate resistance from North Carolina officials. State leaders and local stakeholders have raised concerns about consolidation, competition and community impact, threatening regulatory scrutiny that could delay or reshape the deal. Expect tense negotiations, press statements and a few dramatic headlines.

Chiesi signs $1.9B deal to acquire KalVista and its approved drug

Kyle LaHucik / endpoints - Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KALV} in cash to buy the ...

AI Summary: Chiesi Group agreed to buy KalVista for $1.9 billion to secure an approved therapy and expand its rare-disease footprint. The deal transfers marketed assets and R&D capacity, positioning Chiesi to scale rare-disease revenues and invest in next-wave therapeutics — essentially a big check for a bigger strategic play.

Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors

Frank Vinluan / medcitynews - Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance. The post El…

AI Summary: Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million, adding small‑molecule oncology assets to its pipeline. The deal accelerates Lilly’s tumor‑targeting strategy, reflects Big Pharma’s preference for buying nimble biotech innovation, and highlights ongoing consolidation trends that determine where promising oncology programs ultimately end up.

Gilead Activates Its Pipeline: Option Exercises at Cartography Bio and Kymera Signal Accelerating Oncology Execution

oncodaily - In a pair of announcements that underscore Gilead Sciences’ intensifying commitment to oncology, two of its collaboration partners, Cartography Biosciences and Kymera Therapeutics, revealed today that Gilead has exercised exclusive […]

AI Summary: Gilead moved to accelerate its oncology strategy by exercising option agreements with smaller biotech partners, including Kymera and Cartography Bio. The moves signal targeted investment in protein degraders and other novel modalities, shoring up the company’s mid‑stage pipeline and hinting that big pharma still prefers buying options to inventing overnight.

Orlando Health fleshes out Alabama footprint with another acquisition

fiercehealthcare - The $10 billion nonprofit plans to acquire RMC Health System from the City of Anniston, building on 2024's big-ticket purchase of five Alabama hospitals from Tenet Healthcare.

AI Summary: Orlando Health continued its regional growth by acquiring an Alabama health system, extending its clinical and operational footprint into the state. The move aims to integrate services, expand care access and consolidate regional networks as health systems seek scale to manage costs and enhance specialty offerings.

Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs

Kyle LaHucik / endpoints - In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis. The California biopharma could pay out another $1.85 billion down the road ...

AI Summary: Gilead Sciences struck a multibillion-dollar acquisition to add Tubulis and bolster its oncology pipeline, buying into antibody-drug conjugate technology. The deal signals Gilead’s strategic pivot to expand beyond infectious disease into cancer therapeutics, accelerating access to novel modalities and reshaping competitive dynamics in biopharma.

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio

oncodaily - Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics, marking a strategic expansion into rare disease treatments and strengthening its late-stage pipeline. The deal signals continued consolidation […]

AI Summary: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, picking up Soleno’s Prader‑Willi treatment candidate and bolstering its rare‑disease portfolio. The purchase folds Soleno’s clinical assets and research teams into Neurocrine, positioning the buyer to commercialize a potential high‑value therapy while shoring up long‑term pipeline growth.

Anthropic acquires stealth AI startup Coefficient Bio in $400M deal: reports

fiercehealthcare - AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI startup Coefficient Bio in a $400 million stock deal, according to reporting from The Information and Eric Newcomer.

AI Summary: Anthropic has acquired stealth biotech Coefficient Bio in a reported $400 million deal, signaling a major push by an AI developer into drug discovery. The acquisition folds computational prowess into wet‑lab capabilities, reshaping who might lead future therapeutic discovery and prompting competitors to wonder if they missed the memo.

CHS sells 180-bed hospital for $459M: 6 things to know

Alan Condon / beckershospitalreview - Franklin, Tenn.-based Community Health Systems on April 1 sold Crestwood Medical Center — a 180-bed hospital in Huntsville, Ala. — to Huntsville Hospital Health System for $459 million. Six things to know: 1. The deal includes all of the assets tied to th…

AI Summary: Community Health Systems has finalized the sale of a 180‑bed Alabama hospital for $459 million, concluding a transaction that reshuffles local care ownership and may prompt operational changes. The closing marks a notable consolidation step in regional hospital markets and raises questions about continuity and access as the new owner assumes control.

Biogen to acquire Apellis for $5.6B

Elizabeth Cairns / endpoints - Biogen has made a $5.6 billion deal to acquire Apellis Pharmaceuticals, the companies announced Tuesday. The deal will allow Biogen to get hold of the kidney disease drug Empaveli and the eye disease therapy Syfovre ...

AI Summary: Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion, a deal pitched as a strategic move to broaden Biogen’s pipeline and bolster its biopharma foothold. Analysts and company spokespeople framed the purchase as value‑accretive, even as skeptics question integration risks and the price tag in a cautious market.

Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition

Frank Vinluan / medcitynews - Centessa Pharmaceuticals’ cleminorexton is part of the orexin agonist drug class, which could introduce a new approach to the treatment of narcolepsy and other sleep disorders. Acquiring Centessa brings Eli Lilly into a group of clinical-stage orexin agon…

AI Summary: Eli Lilly announced a $6.3 billion acquisition of Centessa to secure a promising narcolepsy/sleep-disorder candidate and expand its neuroscience portfolio. The deal fast-tracks Lilly into sleep science, buying late-stage assets rather than relying on in-house miracles — a tidy shortcut to diversifying its neurotherapeutics pipeline.

“Me engañaron”: agentes encadenan a un padre que había ido al ICE a reunirse con sus hijos

Claudia Boyd-Barrett and Renuka Rayasam and Amanda Seitz / kffhealthnews - Se supone que la agencia que cuida a niños que llegan solos al país deben reunirlos pronto con sus familias o cuidadores. Pero cada vez más los usan como “carnada” para arrestar a los padres.

AI Summary: Gilead struck a deal to acquire Ouro Medicines for roughly $1.68–1.7 billion, securing an immune‑modulating autoimmune program intended to reset pathological immune responses. The transaction combines upfront cash and potential milestones, expanding Gilead’s pipeline and signaling continued industry appetite for bolt‑on buys to chase novel therapeutics.